Lucijanic et al. [13], established that obesity increased the risk (odds) of stroke and bleeding in DOACs overall: dabigatran conferring lower efficacy (higher thrombosis/stroke risk) and Factor Xa inhibitors (rivaroxaban, edoxaban, and apixaban) increasing the odds of bleeding (somewhat similar to our result). Here, F10 is linked to Obesity.